Understanding immune responses to SARS-CoV-2 in lymphoma patients
Official title: SARS-CoV-2 immune responses in patients with lymphoma
Funded at Emory University · NIH-10886974 · Data updated 2026-11-12
This study is looking at how well people with non-Hodgkin lymphoma and chronic lymphocytic leukemia respond to COVID-19 vaccines, to better understand their immune responses and help improve vaccination strategies for them.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 23, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $192,888 |
| NIH project number | 1K08AI178093-01A1 |
| Project ID | NIH-10886974 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-Hodgkin lymphoma or chronic lymphocytic leukemia who are receiving or have received treatment.
✕Less likely to help
Patients without a diagnosis of lymphoma or chronic lymphocytic leukemia are unlikely to benefit from this research.
What this research studies
This research investigates how patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia respond to SARS-CoV-2 vaccinations. It focuses on the immune system's ability to produce antibodies and T cells after vaccination, which is often impaired in these patients due to their cancer and its treatments. By analyzing blood samples from over 600 patients, the study aims to identify specific immune responses and how they relate to different lymphoma therapies. This information could help improve vaccination strategies for these vulnerable patients.
Why it matters
Potential benefit: If successful, this research could lead to better vaccination protocols that enhance immune responses in lymphoma patients, reducing their risk of severe COVID-19.
How similar studies have gone: Previous research has shown that immune responses to vaccines can vary significantly in cancer patients, indicating that this area of study is both relevant and necessary.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Chang, Andres — Emory University
- Study coordinator: Chang, Andres
Related research
Other NIH-funded projects on the same topics.
-
SARS-CoV-2 immune responses in lymphoma patients
This grant studies how people with lymphoma respond to COVID-19 vaccines and infection, aiming to understand why antibody and T cell responses can be weaker in NHL/CLL patients.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.